Document is current
Any future updates will be listed below
-
Authors
Cummings, Jeffrey L.
Gonzalez, M. Isabel
Pritchard, Martyn C.
May, Patrick C.
Toledo-Sherman, Leticia M.
Harris, Glenn A.
-
Funding
Funding for this research was provided by:
Rainwater Charitable Foundation
- License Information
-
More Information
Article History
Received: 26 May 2023
Accepted: 28 September 2023
First Online: 6 October 2023
Declarations
:
: Not applicable.
: All authors have consented for this review paper to be published.
: JC has provided consultation to Acadia, Actinogen, Alkahest, AlphaCognition, Aprinoia, AriBio, Biogen, BioVie, Cassava, Cerecin, Corium, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, GAP Innovations, Grifols, Janssen, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Sage Therapeutics, Signant Health, Simcere, Sunbird Bio, Suven, SynapseBio, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies.
